Benzodiazepines

9 min read Last updated April 8, 2026

Clinical use: how they show up in anaesthesia

  • Premedication / anxiolysis / amnesia
    • Midazolam most common: rapid onset, short duration, water-soluble formulation (less venous irritation than diazepam).
    • Aim: anxiolysis + anterograde amnesia; limited analgesia (often worsens pain perception if used alone).
  • Procedural sedation (endoscopy, cardioversion, radiology, ED)
    • Titrate to effect; synergistic respiratory depression with opioids and other sedatives (propofol).
    • Midazolam common; diazepam sometimes used (longer duration, active metabolites).
  • Induction adjunct / co-induction
    • Reduces induction dose of propofol/thiopentone; may improve haemodynamic stability but increases risk of apnoea when combined with opioids.
  • Seizure management
    • First-line acute termination: IV lorazepam (often preferred) or IV diazepam; midazolam IM/buccal/intranasal alternatives.
    • Follow with longer-acting antiepileptic to prevent recurrence (e.g., levetiracetam/phenytoin) because benzodiazepine effect may wear off.
  • Alcohol withdrawal / ICU sedation
    • Chlordiazepoxide/diazepam commonly for withdrawal (long-acting); in ICU, midazolam infusion sometimes used but accumulation/delirium risk.
  • Spinal/epidural adjunct (rare now)
    • Preservative-free midazolam has been studied; not routine in UK practice—safety/benefit considerations.

Practical prescribing: typical adult doses (titrate; local policy varies)

  • Midazolam IV for anxiolysis/sedation
    • Incremental 0.5–1 mg every 1–2 min; many adults 1–3 mg total; elderly/frail often 0.5–1 mg total.
    • Onset ~1–2 min; peak 3–5 min; duration 20–60 min (longer with age/organ dysfunction).
  • Diazepam IV for sedation / seizures
    • Sedation: small increments (e.g., 2.5 mg) to effect; seizures: 5–10 mg IV, repeat if needed (per guideline).
    • Formulation contains propylene glycol → venous irritation, thrombophlebitis; avoid small veins.
  • Lorazepam IV for status epilepticus
    • Commonly 4 mg IV (adult), may repeat once after 10–15 min depending on protocol; slower redistribution than diazepam → longer anticonvulsant effect.
  • Flumazenil (reversal)
    • IV 0.2 mg over 15 s, then 0.1 mg every 60 s to desired consciousness (typical total 0.3–1 mg; max often 2 mg, higher in some protocols).
    • Short duration (often 30–60 min) → re-sedation possible, especially after long-acting benzodiazepines.

Core pharmacology

  • Class and examples
    • Short/intermediate: midazolam, lorazepam, temazepam.
    • Long acting: diazepam, chlordiazepoxide; many have active metabolites.
  • Mechanism of action
    • Bind benzodiazepine site on GABA-A receptor (between α and γ subunits) → increases frequency of chloride channel opening in presence of GABA → neuronal hyperpolarisation.
    • Ceiling effect (depend on endogenous/exogenous GABA) → generally safer than barbiturates for respiratory/cardiovascular depression when used alone.
  • Clinical effects
    • Sedation/hypnosis, anxiolysis, anterograde amnesia, anticonvulsant, muscle relaxation.
    • No intrinsic analgesia; may reduce MAC of volatile agents and reduce opioid requirements indirectly via anxiolysis.
  • Pharmacokinetics (high-yield contrasts)
    • High lipid solubility → rapid CNS entry; redistribution contributes to offset after single bolus (esp diazepam).
    • Midazolam is water soluble in vial (acidic pH; ring closed), becomes lipid soluble at physiological pH (ring opens) → rapid onset.
    • Hepatic metabolism: CYP3A4 important for midazolam; interactions with macrolides, azoles, protease inhibitors, grapefruit juice (↑ effect).
    • Diazepam: hepatic metabolism to active metabolites (desmethyldiazepam/nordiazepam, oxazepam, temazepam) → prolonged sedation, especially elderly.
    • Lorazepam: glucuronidation (less CYP dependence) → fewer drug interactions; still prolonged in severe hepatic dysfunction.
    • Context-sensitive half-time: increases with infusion duration (notably midazolam) due to tissue accumulation.
  • Pharmacodynamics and synergy
    • Marked synergy with opioids, propofol, alcohol and other CNS depressants → apnoea/airway obstruction risk even with “small” doses.
    • Elderly, OSA, COPD, obesity, frailty: increased sensitivity and reduced clearance → use lower doses and slower titration.

Organ system effects (FRCA patterns)

  • Respiratory
    • Dose-dependent depression of ventilatory response to CO2; upper airway obstruction common during sedation.
    • Greatly potentiated by opioids; anticipate need for airway manoeuvres and assisted ventilation.
  • Cardiovascular
    • Mild reduction in SVR and BP; minimal direct myocardial depression at sedative doses; hypotension more likely with hypovolaemia, sepsis, co-induction, elderly.
  • CNS / ICP
    • Generally reduce cerebral metabolic rate and cerebral blood flow; maintain/possibly improve cerebral perfusion if BP maintained.
    • Can cause paradoxical agitation/disinhibition (more in children, elderly, psychiatric disease).
  • Other
    • Central muscle relaxant effect; may worsen airway collapsibility in OSA.
    • Minimal histamine release; allergy rare.

Adverse effects, cautions, contraindications

  • Common adverse effects
    • Over-sedation, respiratory depression/apnoea, airway obstruction, hypotension (esp with co-administered agents).
    • Delirium (especially ICU, elderly), psychomotor impairment, falls risk.
  • Paradoxical reactions
    • Restlessness, aggression, involuntary movements; manage with reassurance, reduce stimuli; consider small dose propofol or antipsychotic; flumazenil may help but weigh seizure risk.
  • Dependence and withdrawal
    • Long-term use → tolerance and dependence; abrupt cessation → anxiety, tremor, insomnia, seizures; important in perioperative history.
  • Special populations
    • Elderly: increased sensitivity, prolonged effect → reduce dose and titrate slowly.
    • Hepatic impairment: reduced clearance (esp diazepam/midazolam); lorazepam often less affected (glucuronidation) but still caution.
    • Renal failure: active metabolites (diazepam) may accumulate; midazolam metabolites can accumulate in critical illness/renal dysfunction.
    • Pregnancy: crosses placenta; neonatal depression possible; avoid routine premed; if used, be prepared for neonatal resuscitation.

Flumazenil (benzodiazepine antagonist) — key points

  • Mechanism
    • Reverses sedation/psychomotor impairment; does not reverse respiratory depression due to opioids or other sedatives.
  • Indications
    • Iatrogenic over-sedation (procedural sedation, anaesthesia).
    • Diagnostic/therapeutic trial in suspected isolated benzodiazepine overdose (with caution).
  • Risks / contraindications (exam favourites)
    • Can precipitate seizures in: mixed overdose with pro-convulsants (e.g., TCAs), benzodiazepine dependence, epilepsy treated with benzodiazepines.
    • Short duration → re-sedation; observe and consider infusion in selected cases (specialist setting).
Describe the mechanism of action of benzodiazepines at the GABA-A receptor and contrast with barbiturates.

Expected structure: receptor site → channel effect → dependence on GABA → clinical implications.

  • Benzodiazepines bind to the benzodiazepine site on the GABA-A receptor at the α–γ subunit interface.
  • They are positive allosteric modulators: increase the frequency of chloride channel opening in the presence of GABA → hyperpolarisation.
  • They have a ceiling effect because they do not directly open the channel without GABA (relative safety when used alone).
  • Barbiturates increase the duration of channel opening and at high doses can directly activate GABA-A → greater risk of profound CNS/respiratory depression.
Midazolam is described as water soluble in the ampoule but lipid soluble in the body. Explain why and why it matters clinically.

This is a common FRCA pharmacology viva: chemical form, pH dependence, onset and venous irritation.

  • Midazolam is formulated in an acidic solution where it exists predominantly in a water-soluble ionised/ring-closed form.
  • At physiological pH, the molecule shifts to a more lipid-soluble form → rapid CNS penetration and onset.
  • Clinical consequences: less pain/irritation on injection than diazepam; fast onset makes it suitable for titrated sedation.
Compare midazolam, diazepam and lorazepam in terms of onset, duration, metabolism and clinically important metabolites.

Aim for a table-like verbal answer: formulation/solubility, redistribution, metabolism, active metabolites, typical use.

  • Midazolam: rapid onset; relatively short after bolus but prolonged with infusion; hepatic CYP3A4 metabolism; active metabolites can accumulate in critical illness/renal dysfunction; strong interaction potential (azoles/macrolides).
  • Diazepam: very lipid soluble → rapid onset; long duration due to redistribution + active metabolites (nordiazepam/oxazepam/temazepam) → prolonged sedation; formulation with propylene glycol causes venous irritation.
  • Lorazepam: intermediate onset; longer anticonvulsant effect than diazepam (less rapid redistribution); mainly glucuronidation (fewer CYP interactions); no major active metabolites of the same clinical significance as diazepam.
A patient becomes apnoeic after 2 mg midazolam and 50 micrograms fentanyl for endoscopy. Explain the physiology/pharmacology and how you would manage it.

This is a frequent sedation scenario: synergy, airway obstruction, stepwise management, reversal agents and observation.

  • Cause: synergistic ventilatory depression (reduced CO2 response) + increased upper airway collapsibility from benzodiazepine sedation; fentanyl adds respiratory depression and chest wall rigidity rarely.
  • Immediate management: call for help, stop procedure, airway manoeuvres (chin lift/jaw thrust), high-flow O2, suction, consider adjuncts (OPA/NPA), support ventilation with bag-mask; monitor capnography if available.
  • If inadequate: consider naloxone (opioid reversal) and/or flumazenil (benzodiazepine reversal) depending on likely dominant agent; beware acute pain, agitation, aspiration risk.
  • After recovery: observe for re-sedation (especially if long-acting agents used), document event, review dosing strategy and patient factors (age, OSA, frailty).
Outline the indications, dosing and major risks of flumazenil.

Common FRCA short note: mechanism, dose, duration, seizure risk, re-sedation, when not to use.

  • Indications: reversal of iatrogenic benzodiazepine sedation; selected cases of suspected isolated benzodiazepine overdose.
  • Dose: 0.2 mg IV over 15 s, then 0.1 mg IV every 60 s to effect (typical 0.3–1 mg; max per protocol).
  • Risks: seizures (mixed overdose e.g. TCA, benzodiazepine dependence, epilepsy treated with benzodiazepines), agitation, arrhythmias rarely; re-sedation due to short half-life.
  • If used: ensure airway/ventilation support available; observe after administration; consider repeat dosing/infusion only in monitored settings.
Explain why benzodiazepines can reduce MAC of volatile agents and how this influences anaesthetic technique.
  • Benzodiazepines enhance inhibitory GABAergic neurotransmission → sedation/hypnosis and reduced arousal → reduced MAC requirement for volatiles.
  • Practical implications: lower volatile concentration may be needed; beware hypotension when combining multiple hypnotics; do not mistake amnesia for adequate depth/analgesia.
Discuss the effects of benzodiazepines on cerebral physiology (CBF, CMRO2, ICP) and their role in neuroanaesthesia.
  • They generally decrease CMRO2 and decrease CBF, leading to reduced ICP provided ventilation and haemodynamics are controlled.
  • Main limitation is systemic effects (hypoventilation → hypercapnia → ↑ CBF/ICP; hypotension → ↓ CPP).
A 78-year-old with frailty and OSA needs sedation for a painful procedure. How does age/OSA change your benzodiazepine plan?
  • Increased pharmacodynamic sensitivity and reduced clearance → use much smaller doses, slow titration, allow time to peak effect.
  • OSA increases risk of upper airway obstruction; prioritise positioning, airway adjunct readiness, capnography, and consider alternatives (local/regional, minimal sedation).
  • Avoid combining with opioids where possible; if needed, reduce both and titrate one agent at a time.
Why is lorazepam often preferred to diazepam for status epilepticus (where available)?
  • Lorazepam has less rapid redistribution from brain to peripheral tissues than diazepam → longer duration of anticonvulsant effect after IV dose.
  • Diazepam terminates seizures quickly but effect may wear off sooner, risking recurrence unless followed by longer-acting antiepileptic therapy.
Describe important drug interactions with midazolam and the mechanism.
  • Midazolam is metabolised by CYP3A4.
  • CYP3A4 inhibitors (e.g., azole antifungals, macrolides, protease inhibitors, grapefruit) can markedly increase and prolong sedation/respiratory depression.
  • Enzyme inducers (e.g., rifampicin, some anticonvulsants) may reduce effect; clinical relevance depends on chronicity and dose.
Explain context-sensitive half-time and why midazolam infusions can lead to delayed waking in ICU.
  • Context-sensitive half-time is the time for plasma concentration to fall by 50% after stopping an infusion; it depends on infusion duration and redistribution/metabolism.
  • With prolonged midazolam infusion, drug accumulates in peripheral compartments; on stopping, it redistributes back to plasma and clearance may be reduced in critical illness → delayed emergence.
List the main adverse effects of benzodiazepines relevant to perioperative practice and how you mitigate them.
  • Respiratory depression/airway obstruction: titrate slowly, avoid opioid co-administration if possible, use monitoring (including capnography), be ready to support ventilation.
  • Hypotension: avoid large boluses, correct hypovolaemia, consider alternative agents in unstable patients.
  • Delirium/falls (elderly): avoid routine premed, minimise dose, consider non-pharmacological anxiolysis.
  • Paradoxical agitation: recognise early, reduce stimulation, consider alternative sedation strategy; flumazenil only with careful risk assessment.

0 comments